Xing, Z., Yang, T., Li, X., Xu, H., Hong, Y., Shao, S., . . . Wei, Y. High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy. Elsevier.
Chicago Style (17th ed.) CitationXing, Zhuo, et al. High-glucose-associated YTHDC1 Lactylation Reduces the Sensitivity of Bladder Cancer to Enfortumab Vedotin Therapy. Elsevier.
MLA (9th ed.) CitationXing, Zhuo, et al. High-glucose-associated YTHDC1 Lactylation Reduces the Sensitivity of Bladder Cancer to Enfortumab Vedotin Therapy. Elsevier.
Warning: These citations may not always be 100% accurate.